These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 23290628)

  • 1. HIV-1 entry inhibitors: recent development and clinical use.
    Henrich TJ; Kuritzkes DR
    Curr Opin Virol; 2013 Feb; 3(1):51-7. PubMed ID: 23290628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
    Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 entry inhibitors: an overview.
    Kuritzkes DR
    Curr Opin HIV AIDS; 2009 Mar; 4(2):82-7. PubMed ID: 19339945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Conclusions and perspectives. Maraviroc].
    Alcamí J
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():49-54. PubMed ID: 19133222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: are they the next novel therapies?
    Idemyor V
    HIV Clin Trials; 2005; 6(5):272-7. PubMed ID: 16306033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
    Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.
    Kramer VG; Schader SM; Oliveira M; Colby-Germinario SP; Donahue DA; Singhroy DN; Tressler R; Sloan RD; Wainberg MA
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4154-60. PubMed ID: 22615275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mechanisms of resistance and failure of treatment with maraviroc].
    Delgado R
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():28-33. PubMed ID: 19133219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
    Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
    Panos G; Watson DC
    Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utility of maraviroc.
    Parra J; Portilla J; Pulido F; Sánchez-de la Rosa R; Alonso-Villaverde C; Berenguer J; Blanco JL; Domingo P; Dronda F; Galera C; Gutiérrez F; Kindelán JM; Knobel H; Leal M; López-Aldeguer J; Mariño A; Miralles C; Moltó J; Ortega E; Oteo JA
    Clin Drug Investig; 2011; 31(8):527-542. PubMed ID: 21595497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics, interactions and mechanism of action of maraviroc].
    Soriano V; Poveda E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():12-6. PubMed ID: 19133216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
    Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
    Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker].
    Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():23-7. PubMed ID: 19133218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.
    Yost R; Pasquale TR; Sahloff EG
    Am J Health Syst Pharm; 2009 Apr; 66(8):715-26. PubMed ID: 19336831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of viral entry.
    Melby T; Westby M
    Handb Exp Pharmacol; 2009; (189):177-202. PubMed ID: 19048201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists].
    McKinnell JA; Saag MS
    Curr Opin HIV AIDS; 2009 Nov; 4(6):513-7. PubMed ID: 20048719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection.
    Caldwell DJ; Evans JD
    Expert Opin Pharmacother; 2008 Dec; 9(18):3231-42. PubMed ID: 19040343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maraviroc.
    Fadel H; Temesgen Z
    Drugs Today (Barc); 2007 Nov; 43(11):749-58. PubMed ID: 18174962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.